Growth Hormone Peptides: What They Are and How They Work

Growth hormone (GH) is one of the most important hormones in the human body. It peaks during puberty and gradually declines with age, and that decline is associated in the literature with increased body fat, decreased muscle mass, poor sleep architecture, and slower recovery from injury.

What Are GH-Releasing Peptides?

Rather than administering synthetic growth hormone directly, GH-releasing peptides are studied for their ability to stimulate the body's own growth hormone production via the pituitary-GH axis.

Commonly Studied GH Peptides

CJC-1295

A modified version of growth hormone-releasing hormone (GHRH) that has a longer half-life, meaning it remains active for longer. Frequently studied in combination with Ipamorelin for a complementary mechanism.

Ipamorelin

One of the more receptor-selective GH-releasing peptides studied. It stimulates GH release without significantly affecting cortisol or prolactin levels, making it a common choice in research designs that require pathway specificity.

MK-677 (Ibutamoren)

Technically not a peptide but a growth hormone secretagogue. It is orally bioavailable and increases GH and IGF-1 levels. Studied for its convenience relative to injectable analogs, though research has associated it with increased appetite and water retention.

GHRP-6 and GHRP-2

Older-generation GH-releasing peptides still widely studied. GHRP-6 is associated with a pronounced appetite-stimulating effect, a variable of specific interest in metabolic research.

Effects Associated With GH-Axis Modulation in Research

• •Body composition changes (reduced fat mass, increased lean mass) in study models
• •Sleep-architecture changes, particularly deep-sleep stages
• •Recovery-marker changes following exercise-induced or injury models
• •Skin-quality and elasticity measures
• •Cognitive-function measures in some study designs

Research Design Considerations

GH-axis peptides are not compounds to study casually. Because they interact with the endocrine system, appropriate experimental controls, dosing-response design, and monitoring protocols (including relevant bloodwork endpoints) are standard components of a rigorous research design.

Quality matters enormously, pharmaceutical-grade peptides from trusted, third-party-tested sources are essential for generating reliable research data.

A Quick Refresher on the GH Axis

Your body releases growth hormone (GH) in pulses, mostly during deep sleep and after high-intensity exercise. The hypothalamus drives this rhythm via two opposing signals: growth-hormone-releasing hormone (GHRH) stimulates the pituitary, while somatostatin inhibits it. GH then acts directly on tissues and indirectly via IGF-1, which is produced primarily in the liver. By age 40, total GH output is roughly half of what it was at age 20, and the pulsatile pattern flattens. That decline is what GH-targeting peptides try to address.

Two Mechanism Families

Modern GH-targeting peptides fall into two groups:

• •GHRH analogs, molecules like Sermorelin, CJC-1295, and Tesamorelin mimic the body's natural GHRH and bind to the GHRH receptor on the pituitary.
• •Ghrelin receptor agonists (GHRPs / GH secretagogues), molecules like Ipamorelin, GHRP-2, GHRP-6, Hexarelin, and the oral compound MK-677 bind to the ghrelin receptor and trigger GH release through a parallel pathway.

These two pathways are complementary. Stacking a GHRH analog with a GHRP produces a larger, more physiological GH pulse than either alone, which is why CJC-1295 + Ipamorelin became the canonical research stack.

CJC-1295 in More Detail

CJC-1295 is a modified GHRH analog. The "DAC" (Drug Affinity Complex) version contains a maleimide group that covalently binds to plasma albumin, extending the half-life from minutes to roughly 6–8 days (1). The "no-DAC" version (also called Mod GRF 1-29 or Modified GRF 1-29) lacks that group and acts on a much shorter timescale, typically used when researchers want a clean pulse rather than continuous elevation. Choice of variant matters significantly for protocol design.

Ipamorelin, The Selective GHRP

Ipamorelin is widely considered the cleanest GHRP because it stimulates GH release with minimal effect on cortisol or prolactin (2), which is not true of GHRP-2 or GHRP-6. That selectivity makes it the default choice when researchers want GH-axis activation without confounding hormonal noise.

Tesamorelin, The Pharmaceutical-Grade GHRH Analog

Tesamorelin (brand name Egrifta) is FDA-approved for HIV-associated lipodystrophy. It is a stabilized GHRH analog with strong visceral adipose reduction in a randomized placebo-controlled trial (3). Among GH peptides, Tesamorelin has the most rigorous human RCT evidence, it sits in a different evidentiary class than the other compounds discussed here.

MK-677 (Ibutamoren), The Oral Outlier

MK-677 is a non-peptide oral GH secretagogue that activates the ghrelin receptor. It is convenient (oral, once-daily, long half-life) but produces substantial appetite increase, water retention, and a sustained, not pulsatile, elevation of GH and IGF-1. The sustained elevation is mechanistically different from natural GH release and is one reason some researchers prefer pulsatile GHRP/GHRH protocols instead.

What the GH Axis Actually Does

When GH and IGF-1 rise into a healthier range, the downstream effects most consistently reported in research include:

• •Improved body composition, reduced visceral and subcutaneous fat, modest lean-mass gains
• •Better deep-sleep architecture, GH peaks during slow-wave sleep, and stimulation can deepen that pulse
• •Faster connective-tissue recovery, collagen synthesis is GH/IGF-1-dependent
• •Skin elasticity improvements, dermal collagen turnover responds to GH signaling
• •Cognitive effects, IGF-1 has CNS effects, though human cognitive data is mixed

Reported Risks in the Literature

The GH axis is not a system studied casually:

• •Insulin resistance, sustained GH elevation has been shown to blunt insulin sensitivity in study models; fasting glucose and HbA1c are standard monitoring endpoints.
• •Edema and joint discomfort, reported at higher doses in study populations, generally dose-dependent.
• •IGF-1 ceiling effects, research designs typically track IGF-1 via periodic bloodwork to stay within defined study parameters.
• •Cycling in study design, published research protocols vary in how GH peptide administration is cycled, generally to study receptor-sensitivity effects over time.

How Research Protocols Are Typically Structured

Published and community research literature on the CJC-1295 (no-DAC) + Ipamorelin combination commonly involves baseline and interim bloodwork (IGF-1, fasting glucose, HbA1c, lipid panel) to track study endpoints over a defined study period. This article does not provide dosing, administration, or cycling guidance of any kind; researchers should consult the primary literature and their institution's own protocols.

Summary

GH-targeting peptides are among the better-characterized classes in the research peptide literature. The mechanism is well understood, and the reported adverse-effect profile is manageable in research designs that use conservative dosing parameters and biomarker tracking. Quality sourcing matters as much as protocol design, under-dosed or impure GH peptides will produce no measurable research signal at all.

References

1. Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006 Mar;91(3):799-805. PMID: 16352683.
2. Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998 Nov;139(5):552-61. PMID: 9849822.
3. Falutz J, Potvin D, Mamputu JC, et al. Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension. J Acquir Immune Defic Syndr. 2010 Mar;53(3):311-22. PMID: 20101189.